Tuesday 27 September 2022 - 04:19
In Business 42 Years - Since 1980
Recently, we have been and are currently operating with: (1) staff shortages related to CV19 and other factors, (2) vacations, (3) a significant health burden for one senior staff member, and (4) dedication of substantial internal resources to a major public-service project. This situation is expected to continue through Sunday, September 11. During this time, we have been and expect to continue entering, processing and shipping orders normally for in-stock products. However, non-order-related communications and production of backordered products will be subject to some unusual delays. We apologize very much for this situation and appreciate your understanding.
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
P-7600 PKC412, >99%
Synonyms : [CGP41251] [4'-N-Benzoyl Staurosporine] [Midostaurin]
Related Terms : [Rydapt]
- Size
- US $
- €
- £
- ¥
- 1 mg
- 41
- 42
- 37
- 5,900
- Add to Cart
- Out of stock
- 5 mg
- 99
- 102
- 91
- 14,300
- Add to Cart
- Out of stock
- 10 mg
- 166
- 172
- 153
- 24,000
- Add to Cart
- Out of stock
- 25 mg
- 331
- 343
- 306
- 47,800
- Add to Cart
- Out of stock
- 50 mg
- 459
- 475
- 425
- 66,200
- Add to Cart
- Out of stock
- 100 mg
- 775
- 803
- 717
- 111,800
- Add to Cart
- Out of stock
- 200 mg
- 1,290
- 1,337
- 1,194
- 186,100
- Add to Cart
- Out of stock
- 500 mg
- 1,870
- 1,939
- 1,731
- 269,800
- Add to Cart
- Out of stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 570.64
- C35H30N4O4
- [120685-11-2]
- M.I. 14: 6185
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 100 mg/mL; soluble in ethanol at 5 mg/mL with warming; very poorly soluble in water; maximum solubility in plain water is estimated to be about 10-20 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A.
- The staurosporine analog, PKC412, inhibits a variety of serine/threonine and tyrosine kinases including PKC (IC50 = 50 nM), cyclic AMP-dependent protein kinase (IC50 = 2.4 µM), S6 kinase (IC50 = 5.0 µM), and EGFR (epidermal growth factor receptor) tyrosine-kinase activity (IC50 = 3.0 µM). Meyer, T., et al. "A derivative of staurosporine (CGP 41 251) shows selectivity for protein kinase C inhibition and in vitro anti-proliferative as well as in vivo anti-tumor activity." Int. J. Cancer 43: 851-856 (1989).
- PKC412 inhibits autophosphorylation of platelet-derived growth factor (PDGF) receptor in BALB/c 3T3 cells at submicromolar concentrations. Andrejauskas-Buchdunger, E. and Regenass, U. "Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251." Cancer Research, 52: 5353-5358 (1992).
- PKC412 strongly blocks the proliferation of ras-transformed pancreatic cancer cells (TUC-3) by causing apoptosis and induction of phenotypic reversion. Way, D., et al. "A protein kinase C inhibitor induces phenotypic reversion of ras-transformed pancreatic cancer cells and cooperatively blocks tumor cell proliferation with an anti-ras peptide." Cancer Chemother. Pharmacol. 49: 429-437 (2002).
- PKC412 suppresses Akt activity by blocking serine phosphorylation in the kinase activation loop and induces apoptosis in myeloma cell lines. Bahlis, N.J., et al. "N-Benzoylstaurosporine (PKC412) inhibits Akt kinase inducing apoptosis in multiple myeloma cells." Leuk. Lymphoma 46: 899-908 (2005).
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- PKC412 selectively inhibits T lymphocyte production of TNF-α (tumor necrosis factor - alpha) with an IC50 of 0.5 µM. Si, M.S., et al. "Effects of the kinase inhibitor CGP41251 (PKC 412) on lymphocyte activation and TNF-alpha production." Int. Immunopharmacol. 5: 1141-11419 (2005).
- Not available in some countries; not available to some institutions; may not be sold for some uses.
